Krystal Biotech, Inc. (KRYS)
300.75
+0.50
(+0.17%)
USD |
NASDAQ |
Nov 06, 16:00
299.88
-0.87
(-0.29%)
After-Hours: 16:56
Krystal Biotech Research and Development Expense (Annual) : 52.32M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 52.32M |
| December 31, 2024 | 53.57M |
| December 31, 2023 | 46.43M |
| December 31, 2022 | 39.86M |
| December 31, 2021 | 26.08M |
| Date | Value |
|---|---|
| December 31, 2020 | 17.94M |
| December 31, 2019 | 15.62M |
| December 31, 2018 | 7.761M |
| December 31, 2017 | 3.208M |
| December 31, 2016 | 0.741M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| TG Therapeutics, Inc. | 160.22M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Ionis Pharmaceuticals, Inc. | 913.18M |
| Ultragenyx Pharmaceutical, Inc. | 723.00M |
| BridgeBio Pharma, Inc. | 451.95M |